METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression

N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and ne...

Full description

Saved in:
Bibliographic Details
Published inExperimental hematology & oncology Vol. 11; no. 1; pp. 14 - 16
Main Authors Guo, Yu-Qing, Wang, Qiang, Wang, Jun-Guo, Gu, Ya-Jun, Song, Pan-Pan, Wang, Shou-Yu, Qian, Xiao-Yun, Gao, Xia
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 14.03.2022
BioMed Central
BMC
Subjects
CDC25B
Cell cycle
Comparative analysis
Development and progression
Health aspects
HNSCC
Immunohistochemistry
m6A
Messenger RNA
Metastasis
Methylation
Methylene blue
Methyltransferases
METTL3
Prognosis
Squamous cell carcinoma
China
m6A
HNSCC
Cell cycle
METTL3
CDC25B
Online AccessGet full text

Cover

More Information
Summary:N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC). The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo. M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression. METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2162-3619
2162-3619
DOI:10.1186/s40164-022-00256-3